JP2008500838A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500838A5
JP2008500838A5 JP2007515472A JP2007515472A JP2008500838A5 JP 2008500838 A5 JP2008500838 A5 JP 2008500838A5 JP 2007515472 A JP2007515472 A JP 2007515472A JP 2007515472 A JP2007515472 A JP 2007515472A JP 2008500838 A5 JP2008500838 A5 JP 2008500838A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
seq
composition
nucleotides
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515472A
Other languages
English (en)
Japanese (ja)
Other versions
JP4906717B2 (ja
JP2008500838A (ja
Filing date
Publication date
Priority claimed from US10/858,013 external-priority patent/US20060135455A1/en
Application filed filed Critical
Publication of JP2008500838A publication Critical patent/JP2008500838A/ja
Publication of JP2008500838A5 publication Critical patent/JP2008500838A5/ja
Application granted granted Critical
Publication of JP4906717B2 publication Critical patent/JP4906717B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007515472A 2004-06-01 2005-06-01 遺伝子発現の阻害に関する方法および組成物 Expired - Fee Related JP4906717B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US10/858,013 US20060135455A1 (en) 2004-06-01 2004-06-01 Methods and compositions for the inhibition of gene expression
US10/858,341 2004-06-01
US10/858,145 2004-06-01
US10/858,164 US7524827B2 (en) 2004-06-01 2004-06-01 Methods and compositions for the inhibition of gene expression
US10/858,146 US20060229267A1 (en) 2004-06-01 2004-06-01 Methods and compositions for the inhibition of gene expression
US10/858,094 US20080152700A1 (en) 2004-06-01 2004-06-01 Methods and compositions for the inhibition of gene expression
US10/858,341 US20050287667A1 (en) 2004-06-01 2004-06-01 Methods and compositions for the inhibition of gene expression
US10/858,164 2004-06-01
US10/858,013 2004-06-01
US10/858,145 US7498315B2 (en) 2004-06-01 2004-06-01 Methods and compositions for the inhibition of gene expression
US10/858,146 2004-06-01
US10/858,094 2004-06-01
US61197404P 2004-09-22 2004-09-22
US60/611,974 2004-09-22
US63721204P 2004-12-17 2004-12-17
US60/637,212 2004-12-17
PCT/US2005/018993 WO2005118824A2 (en) 2004-06-01 2005-06-01 Methods and compositions for the inhibition of gene expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011250762A Division JP5922913B2 (ja) 2004-06-01 2011-11-16 遺伝子発現の阻害に関する方法および組成物

Publications (3)

Publication Number Publication Date
JP2008500838A JP2008500838A (ja) 2008-01-17
JP2008500838A5 true JP2008500838A5 (enExample) 2008-07-17
JP4906717B2 JP4906717B2 (ja) 2012-03-28

Family

ID=35463455

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007515472A Expired - Fee Related JP4906717B2 (ja) 2004-06-01 2005-06-01 遺伝子発現の阻害に関する方法および組成物
JP2011250762A Expired - Fee Related JP5922913B2 (ja) 2004-06-01 2011-11-16 遺伝子発現の阻害に関する方法および組成物
JP2015023485A Pending JP2015133967A (ja) 2004-06-01 2015-02-09 遺伝子発現の阻害に関する方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011250762A Expired - Fee Related JP5922913B2 (ja) 2004-06-01 2011-11-16 遺伝子発現の阻害に関する方法および組成物
JP2015023485A Pending JP2015133967A (ja) 2004-06-01 2015-02-09 遺伝子発現の阻害に関する方法および組成物

Country Status (10)

Country Link
US (6) US20050287667A1 (enExample)
EP (2) EP1773859A4 (enExample)
JP (3) JP4906717B2 (enExample)
CN (1) CN101014608B (enExample)
AU (1) AU2005250453B2 (enExample)
BR (1) BRPI0511770A (enExample)
CA (1) CA2569183A1 (enExample)
ES (1) ES2402532T3 (enExample)
PL (1) PL2141173T3 (enExample)
WO (1) WO2005118824A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3111258B2 (ja) 1991-03-14 2000-11-20 古野電気株式会社 水中探知装置
US20050287667A1 (en) * 2004-06-01 2005-12-29 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US8815599B2 (en) * 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
JP5122474B2 (ja) * 2005-12-01 2013-01-16 プロネイ・セラピューティクス・インコーポレイテッド 両性リポソーム製剤
US20090324587A1 (en) * 2005-12-01 2009-12-31 Neal Clifford Goodwin Cancer Therapies and Pharmaceutical Compositions Used Therein
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2121925A2 (en) * 2007-03-02 2009-11-25 MDRNA, Inc. Nucleic acid compounds for inhibiting ras gene expression and uses thereof
US9023819B2 (en) * 2008-06-09 2015-05-05 National Chung Cheng University Treatment of a disease or a condition associated with aberrant gene hypomethylation by a method involving tailored epigenomic modification
US11536713B2 (en) 2009-12-25 2022-12-27 Chugai Seiyaku Kabushiki Kaisha Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein
SG189302A1 (en) 2010-10-06 2013-05-31 Pharmalogicals Res Pte Ltd Cancer stem cell population and method for production thereof
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US8734859B1 (en) 2010-11-13 2014-05-27 Sirbal Ltd. Molecular combinations for cancer or other disease treatment
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US8541382B2 (en) 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
US20170049687A1 (en) 2015-07-29 2017-02-23 Sirbal Ltd. Herbal Combinations For Treating Scalp Conditions
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
EP3603671A3 (en) 2011-10-28 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi
WO2013183964A1 (ko) * 2012-06-07 2013-12-12 한양대학교 산학협력단 폐암 진단 및 치료를 위한 표적 단백질
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
CN104884637A (zh) 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
WO2014144942A2 (en) * 2013-03-15 2014-09-18 Pronai Therapeutics, Inc. Dnai for the modulation of genes
WO2015082950A1 (en) 2013-12-02 2015-06-11 Sirbal Ltd. Herbal combinations for treatment of a skin condition
EP3083960B1 (en) 2013-12-16 2021-02-03 Syddansk Universitet Ras exon 2 skipping for cancer treatment
CN105581979A (zh) * 2016-02-24 2016-05-18 南京大学 一种抑制her-2表达的核酸脂质体纳米药物及其制备方法和应用
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
EP3618838A1 (en) * 2017-05-04 2020-03-11 Sanofi Methods for treatment of alport syndrome
JP7427227B2 (ja) * 2020-01-21 2024-02-05 学校法人産業医科大学 腫瘍細胞の生存を低下させるｋｒａｓアンチセンスオリゴヌクレオチド及びその用途
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
WO1992020698A1 (en) * 1991-05-17 1992-11-26 Uab Research Foundation Sequence specific dna binding drugs
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5582986A (en) * 1991-06-14 1996-12-10 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5994069A (en) 1996-01-24 1999-11-30 Third Wave Technologies, Inc. Detection of nucleic acids by multiple sequential invasive cleavages
US5792608A (en) * 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
WO1994017086A1 (en) 1993-01-25 1994-08-04 Apollon, Inc. Gene regulation by targeting putative intramolecular triple helix
AU6044994A (en) * 1993-02-19 1994-09-14 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
EP0707653B1 (en) 1993-06-11 2004-09-01 Commonwealth Scientific And Industrial Research Organisation Method for specific silencing of genes by dna methylation
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
WO1995017507A1 (en) * 1993-12-23 1995-06-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5844107A (en) 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5518885A (en) * 1994-04-19 1996-05-21 The United States Of America As Represented By The Department Of Health & Human Services ERBB2 promoter binding protein in neoplastic disease
US6221959B1 (en) * 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
WO1996018732A2 (en) 1994-12-15 1996-06-20 Board Of Trustees Of The University Of Illinois Sequence-specific inhibition of dna synthesis by triplex-forming oligonucleotides
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
WO1997014440A1 (en) 1995-10-19 1997-04-24 Johnson & Johnson Interventional Systems Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia
DE19542372A1 (de) 1995-11-14 1997-05-15 Bayer Ag Acylierte 5-Aminoisothiazole
US6379966B2 (en) 1999-02-26 2002-04-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
CA2239957A1 (en) 1995-12-22 1997-07-03 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US6126964A (en) 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US5985557A (en) 1996-01-24 1999-11-16 Third Wave Technologies, Inc. Invasive cleavage of nucleic acids
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
CA2289702C (en) * 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6291673B1 (en) 1997-10-17 2001-09-18 Purdue Research Foundation Folic acid derivatives
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
CN1333678A (zh) * 1998-05-20 2002-01-30 表达遗传学公司 定向肝细胞的聚乙二醇接枝的聚－l－赖氨酸的聚合基因载体
US6429200B1 (en) 1998-07-17 2002-08-06 Mirus Corporation Reverse micelles for delivery of nucleic acids
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US6458382B1 (en) 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
AU2001250572A1 (en) * 2000-04-07 2001-10-23 Epigenomics Ag Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
US20040006036A1 (en) * 2000-04-12 2004-01-08 Gmr, A Delaware Corporation Silencing transcription by methylation
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
ITMI20012367A1 (it) * 2001-11-09 2003-05-09 Visufarma S R L Oligonucleotidi antisenso che regolano l'espressione del gene antiapoptotico bcl-2
CA2486967A1 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions their methods of preparation and use
AU2003295561A1 (en) * 2002-11-14 2004-06-15 Genta Salus Llc Inhibitory oliogonucleotides targeted to bcl-2
CA2508052A1 (en) 2002-12-05 2004-06-17 Imperial College Innovations Limited Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
WO2004056971A2 (en) * 2002-12-19 2004-07-08 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
ES2344566T3 (es) * 2003-12-23 2010-08-31 Santaris Pharma A/S Compuestos oligomericos para la modulacion de bcl-2.
DE102004054730A1 (de) * 2004-03-28 2006-05-11 Novosom Ag Serumstabile amphotere Liposomen
US20050287667A1 (en) * 2004-06-01 2005-12-29 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression

Similar Documents

Publication Publication Date Title
JP2012085642A5 (enExample)
Jansen et al. Antisense therapy for cancer—the time of truth
US9200285B2 (en) Clusterin antisense therapy for treatment of cancer
US20030229040A1 (en) Cationic liposomal delivery system and therapeutic use thereof
US6559129B1 (en) Cationic liposomal delivery system and therapeutic use thereof
CN1703229B (zh) 治疗前列腺和其他癌的组合物和其制备药物的用途
Brignole et al. Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment
US7262173B2 (en) Chemosensitizing with liposomes containing oligonucleotides
Gleave et al. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer
JP2006503904A5 (enExample)
Yang et al. Gene targets of antisense therapies in breast cancer
Niwa et al. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck
Chen Clinical development of antisense oligonucleotides as anti-cancer therapeutics
JP5406024B2 (ja) Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法
Kuss et al. Antisense-time to shoot the messenger
Sanati et al. Application of RNA-based therapeutics in glioma: A review
Canellos Lymphoma: present and future challenges
WO2005067632A2 (en) Lipid compositions and use thereof
US20210338835A1 (en) Methods for treating subjects suffering from acute myeloid leukemia with flt3 ligand-targeted mir-150 nanoparticles
CN115590839A (zh) 一种高效安全的治疗her2高表达肿瘤的药物
EP1409639A1 (en) Epidermal growth factor receptorantisense oligonucleotides
EP2373309A1 (en) Anticancer combination comprising docetaxel and an antisense oligonucleotide
Dapas et al. Increase in therapeutic index of doxorubicin and vinblastine by aptameric oligonucleotide in human T lymphoblastic drug-sensitive and multidrug-resistant cells
Kausch et al. Antisense oligonucleotide therapy for urologic tumors
EP1667731B1 (en) Bispecific oligonucleotide for the treatment of cns malignancies